GT200900112A - Tratamiento de los trastornos generalizados del desarrollo - Google Patents

Tratamiento de los trastornos generalizados del desarrollo

Info

Publication number
GT200900112A
GT200900112A GT200900112A GT200900112A GT200900112A GT 200900112 A GT200900112 A GT 200900112A GT 200900112 A GT200900112 A GT 200900112A GT 200900112 A GT200900112 A GT 200900112A GT 200900112 A GT200900112 A GT 200900112A
Authority
GT
Guatemala
Prior art keywords
treatment
development
generalized
disorders
generalized disorders
Prior art date
Application number
GT200900112A
Other languages
English (en)
Inventor
Magali Haas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of GT200900112A publication Critical patent/GT200900112A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

LA PRESENTE INVENCION ESTA DIRIGIDA AL USO DE ALGUNOS COMPUESTOS DE CARBAMATO PARA EL TRATAMIENTO DE PACIENTES CON TRASTORNOS GENERALIZADOS DEL DESARROLLO (PDD'S) QUE SON UNA CATEGORIA DE TRASTORNOS NEUROLOGICOS CARACTERIZADOS POR DETERIORO SEVERO Y GENERALIZADO TALES COMO EL AUTISMO.
GT200900112A 2006-10-31 2009-04-30 Tratamiento de los trastornos generalizados del desarrollo GT200900112A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US86359506P 2006-10-31 2006-10-31

Publications (1)

Publication Number Publication Date
GT200900112A true GT200900112A (es) 2010-05-18

Family

ID=39145417

Family Applications (1)

Application Number Title Priority Date Filing Date
GT200900112A GT200900112A (es) 2006-10-31 2009-04-30 Tratamiento de los trastornos generalizados del desarrollo

Country Status (17)

Country Link
US (1) US20080103199A1 (es)
EP (1) EP2089011A1 (es)
JP (1) JP2010508354A (es)
KR (1) KR20090080105A (es)
CN (1) CN101568333A (es)
AU (1) AU2007313911A1 (es)
BR (1) BRPI0718323A2 (es)
CA (1) CA2667909A1 (es)
CO (1) CO6180427A2 (es)
EA (1) EA200970435A1 (es)
GT (1) GT200900112A (es)
IL (1) IL198488A0 (es)
MX (1) MX2009004798A (es)
NI (1) NI200900074A (es)
NO (1) NO20092019L (es)
WO (1) WO2008054984A1 (es)
ZA (1) ZA200903772B (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7702468B2 (en) 2006-05-03 2010-04-20 Population Diagnostics, Inc. Evaluating genetic disorders
US10522240B2 (en) 2006-05-03 2019-12-31 Population Bio, Inc. Evaluating genetic disorders
WO2010020585A1 (en) * 2008-08-18 2010-02-25 INSERM (Institut National de la Santé et de la Recherche Médicale) Serotonin reuptake inhibitors for the treatment of rett syndrome
CN103392182B (zh) 2010-08-02 2017-07-04 众有生物有限公司 用于发现遗传疾病中致病突变的系统和方法
US8609849B1 (en) 2010-11-30 2013-12-17 Fox Chase Chemical Diversity Center, Inc. Hydroxylated sulfamides exhibiting neuroprotective action and their method of use
EP2766483B1 (en) 2011-10-10 2022-03-23 The Hospital For Sick Children Methods and compositions for screening and treating developmental disorders
US11180807B2 (en) 2011-11-04 2021-11-23 Population Bio, Inc. Methods for detecting a genetic variation in attractin-like 1 (ATRNL1) gene in subject with Parkinson's disease
EP2812452B1 (en) 2012-02-09 2020-05-27 Population Bio, Inc. Methods and compositions for screening and treating developmental disorders
SG10201908587PA (en) * 2012-08-06 2019-10-30 S1 Pharmaceuticals Inc Treatment regimens
EP2895621B1 (en) 2012-09-14 2020-10-21 Population Bio, Inc. Methods and compositions for diagnosing, prognosing, and treating neurological conditions
EP2900835A4 (en) 2012-09-27 2016-05-11 Population Diagnotics Inc METHODS AND COMPOSITIONS FOR DETECTING AND TREATING DEVELOPMENTAL DISORDERS
EP2970109A4 (en) * 2013-03-12 2017-01-18 Bio-Pharm Solutions Co., Ltd. Phenyl carbamate compound and a composition for neuroprotection comprising the same
GB2558326B (en) 2014-09-05 2021-01-20 Population Bio Inc Methods and compositions for inhibiting and treating neurological conditions
CN110290788A (zh) * 2016-12-14 2019-09-27 爱思开生物制药株式会社 氨基甲酸酯化合物用于预防、缓解或治疗双相障碍的用途
US10240205B2 (en) 2017-02-03 2019-03-26 Population Bio, Inc. Methods for assessing risk of developing a viral disease using a genetic test
GB2571696B (en) 2017-10-09 2020-05-27 Compass Pathways Ltd Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced
FI3625368T3 (fi) 2018-08-08 2023-01-13 Menetelmiä john cunningham -viruksen aiheuttaman progressiivin multifokaalin leukoenkefalopatian kehittymisen riskin arviointiin geneettisellä testauksella
EP3955936A1 (en) 2019-04-17 2022-02-23 COMPASS Pathfinder Limited Treatment of depression and other various disorders with psilocybin

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4276841B2 (ja) * 2001-02-27 2009-06-10 オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド 精神病性障害の予防もしくは治療における使用のためのカルバメート化合物
NZ527988A (en) * 2001-02-27 2006-01-27 Ortho Mcneil Pharm Inc Carbamate compounds for use in preventing or treating bipolar disorder
RU2294739C2 (ru) * 2001-02-27 2007-03-10 Орто-Макнейл Фармасьютикал, Инк. Производные карбамата для применения для предупреждения или лечения расстройств движений
CN1235579C (zh) * 2001-02-27 2006-01-11 奥索-麦克尼尔药品公司 用于预防或治疗神经变性疾病的氨基甲酸酯化合物
US20060194873A1 (en) * 2004-09-16 2006-08-31 Choi Yong M Methods of treating epileptogenesis and epilepsy

Also Published As

Publication number Publication date
NO20092019L (no) 2009-06-23
CO6180427A2 (es) 2010-07-19
BRPI0718323A2 (pt) 2013-11-26
CN101568333A (zh) 2009-10-28
NI200900074A (es) 2010-02-01
WO2008054984A1 (en) 2008-05-08
MX2009004798A (es) 2009-08-12
EP2089011A1 (en) 2009-08-19
IL198488A0 (en) 2010-02-17
US20080103199A1 (en) 2008-05-01
JP2010508354A (ja) 2010-03-18
AU2007313911A1 (en) 2008-05-08
CA2667909A1 (en) 2008-05-08
EA200970435A1 (ru) 2009-10-30
ZA200903772B (en) 2010-08-25
KR20090080105A (ko) 2009-07-23

Similar Documents

Publication Publication Date Title
GT200900112A (es) Tratamiento de los trastornos generalizados del desarrollo
ECSP077275A (es) Novedosos derivados de heteroarilsulfamida benzofusionados utiles como agentes anticonvulsivos
PA8621901A1 (es) Derivados de sulfonamida para el tratamiento de enfermedades
DOP2006000169A (es) Inhibidores espiropiperidina de beta-secretasa para el tratamiento de la enfermedad de alzheimer
SV2011003802A (es) Derivados de triazol utiles para el tratamiento de enfermedades
AR057239A1 (es) Inmunoglobulinas
UY32883A (es) Anticuerpos humanos de alta afinidad contra el receptor activado por proteasa de tipo 2 humano
ECSP066730A (es) Compuestos y procedimientos para uso
PA8622001A1 (es) Derivados de sulfonamida para el tratamiento de enfermedades
BRPI0518169A (pt) tiazolil-dihidro-indazóis
GT200600430A (es) Compuestos de carboxiamina y metodos de uso de los mismos
ECSP12011979A (es) Nuevos compuestos triciclicos
CR9485A (es) Modulators of indoleamine 2,3-dioxygenase and methods of using the same
UY29802A1 (es) Análogos de la feniletilamina y su uso en el tratamiento del glaucoma
CR10489A (es) Derivados fenil-pirazol como ligandos de receptores glucocorticoides no esteroides
PA8627001A1 (es) Compuestos para el tratamiento de enfermedades
CO6321241A2 (es) Derivados de 1,3,4- tiadiazol espiro condensados para la inhibicion de la actividad de quinesina (ksp)
GT200600161A (es) Nuevas combinaciones terapeuticas para el tratamiento o la prevencion de los trastornos psicoticos
AR047922A1 (es) Nuevos derivados de pentafluorsulfanilo, su obtencion y su utilizacion como agentes farmaceuticos
GT200700103A (es) Compuestos biciclocarboxiamida sustituidos
CO6382118A2 (es) Nuevas octahidrociclopenta(c)ciprol-4aminas sustituidas como bloqueantes de los canales de calcio
CL2008001820A1 (es) Compuestos derivados de aril-isoxasol-imidazol; procedimiento de preparacion; composicion farmaceutica que los contiene; y uso en la preparacion de medicamentos utiles en el tratamiento de trastornos cognitivos y enfermedades relacionadas con alzheimer.
UY30501A1 (es) Neurotrofinas modificadas post-trasduccionalmente
CL2012001031A1 (es) Compuestos derivados de 2-oxo-1-pirrolidinil-imidazotiadiazol; composición farmacéutica que los comprende; útiles para el tratamiento de la epilepsia, transtornos neurológicos, entre otros.
UY28484A1 (es) Compuestos para el tratamiento de trastornos neurodegenerativos